Brickell Biotech Stock Moves Higher After Complete Enrollment In Phase 3 Studies Of Sofpironium Bromide

by Vandana Singh, Benzinga Editor

June 30, 2021 10:50 AM | 1 min read |

Brickell Biotech Inc BBI has announced that the final patient completed the Phase 3 Cardigan I study, and all planned patients have been enrolled in the Phase 3 Cardigan II study.
Both studies evaluate sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis (excessive sweating).
Each study has enrolled approximately 350 subjects nine years of age and older.
The co-primary efficacy endpoints of both studies include the proportion of subjects achieving at least a 2-point improvement on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale and change in gravimetric sweat production.
The Company expects to announce topline results from both the studies in Q4 of 2021.
Price Action: BBI shares are up 6.23% at $0.99 during the market session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Axillary Hyperhidrosis Briefs Phase 3 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.